{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:08:05Z","timestamp":1779401285483,"version":"3.53.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10147-023-02376-0","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T07:03:32Z","timestamp":1688713412000},"page":"1176-1182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-na\u00efve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)"],"prefix":"10.1007","volume":"28","author":[{"given":"Hiroki","family":"Yukami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":false,"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"2376_CR1","doi-asserted-by":"publisher","unstructured":"Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (2020) CA Cancer J Clin 70: 313. https:\/\/doi.org\/10.3322\/caac.21609","DOI":"10.3322\/caac.21609"},{"key":"2376_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4","journal-title":"Lancet Oncol"},{"key":"2376_CR3","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991\u20134997. https:\/\/doi.org\/10.1200\/JCO.2006.06.8429","journal-title":"J Clin Oncol"},{"key":"2376_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","volume":"4","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Boku N, Mizusawa J et al (2019) Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4:501\u2013510. https:\/\/doi.org\/10.1016\/S2468-1253(19)30083-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2376_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s10120-011-0009-5","volume":"14","author":"H Narahara","year":"2011","unstructured":"Narahara H, Iishi H, Imamura H et al (2011) Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301\/TOP-002). Gastric Cancer 14:72\u201380. https:\/\/doi.org\/10.1007\/s10120-011-0009-5","journal-title":"Gastric Cancer"},{"key":"2376_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"2376_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.annonc.2023.01.006","volume":"34","author":"SY Rha","year":"2023","unstructured":"Rha SY, Wyrwicz LS, Weber PEY et al (2023) VP1-2023: pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) cancer: phase III KEYNOTE-859 study. Ann Oncol 34:319\u2013320. https:\/\/doi.org\/10.1016\/j.annonc.2023.01.006","journal-title":"Ann Oncol"},{"key":"2376_CR8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393:1948\u20131957. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"2376_CR9","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK et al (2021) PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol 39:2903\u20132913. https:\/\/doi.org\/10.1200\/JCO.20.02914","journal-title":"J Clin Oncol"},{"key":"2376_CR10","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"15","author":"P Thuss-Patience","year":"2011","unstructured":"Thuss-Patience P, Albrecht K, Dmitry B et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2014a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 15:2306\u20132314. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.002","journal-title":"Eur J Cancer"},{"key":"2376_CR11","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438\u20134444. https:\/\/doi.org\/10.1200\/JCO.2012.48.5805","journal-title":"J Clin Oncol"},{"key":"2376_CR12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"key":"2376_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2022.01.015","volume":"165","author":"S Lorenzen","year":"2022","unstructured":"Lorenzen S, Thuss-Patience P, Pauligk C et al (2022) FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel\u2014results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer 165:48\u201357. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.015","journal-title":"Eur J Cancer"},{"key":"2376_CR14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670\u20131676. https:\/\/doi.org\/10.1200\/JCO.2006.09.0928","journal-title":"J Clin Oncol"},{"key":"2376_CR15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02376-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02376-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02376-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T01:02:42Z","timestamp":1693443762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02376-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02376-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"15 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HY has no competing interests to disclose. HK has received consulting fees from Daiichi-Sankyo Co. Ltd.; honoraria from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., Incyte Biosciences Japan, and Taiho Pharmaceutical Co. Ltd.; lecture fees from Glaxo Smith Kline K.K. and Otsuka Pharmaceutical Co., Ltd.; and research funding from Bristol-Myers Squibb Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical. Co., Ltd., and Eisai Co. Ltd. TY has no competing interests to disclose. DS has received honoraria from Daiichi Sankyo Co. Ltd., and Chugai Pharmaceutical Co., Ltd.; and research funding from Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., Taiho Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. TS has no competing interests to disclose. YK has received honoraria from Taiho Pharmaceutical Co. Ltd. and research funding from Taiho Pharmaceutical Co. Ltd. and Yakult Pharmaceutical Industry. MG has no competing interests to disclose. TS has received honoraria from Daiichi Sankyo Co. Ltd., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd., and Yakult Pharmaceutical Industry; research funding from Daiichi Sankyo Co. Ltd., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd., and Yakult Pharmaceutical Industry.; scholarship donations from Taiho Pharmaceutical Co. Ltd.; and endowed chairs from Ono Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, and Chugai Pharmaceutical Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) Steering Committee and the Institutional Review Boards of all participating hospitals. The current study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. All the patients provided written informed consent prior to initiating chemotherapy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}